Pediatric Study to Evaluate Treatment of Persistent Moderate or Severe Asthma With the Association Fluticasone 250 Mcg/Dose and Salmeterol 50 Mcg/Dose - ADERE PROJECT (ADERE (Ped))

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01476059
First received: March 4, 2010
Last updated: November 17, 2011
Last verified: November 2011
  Purpose

Prospective, parallel-group, randomized study to evaluate the compliance to the treatment of children aged between 6 and 14 years old with persistent moderate or severe asthma, receiving the association Fluticasone 250 mcg/dose and Salmeterol 50 mcg/dose twice a day.

ADERE PROJECT (Pediatric)


Condition Intervention Phase
Asthma
Other: Telephone follow-up
Other: No telephone follow-up
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective, Parallel-group, Randomized Study to Evaluate the Compliance to the Treatment of Children Aged Between 6 and 14 Years Old With Persistent Moderate or Severe Asthma, Receiving the Association Fluticasone 250 Mcg/Dose and Salmeterol 50 Mcg/Dose Twice a Day. ADERE PROJECT

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered. [ Time Frame: After 90 days of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Disease control, evaluated by information in the questionnaires. [ Time Frame: After 90 days of treatment ] [ Designated as safety issue: No ]
  • Regular medical attention sought, evaluated by information in the questionnaires [ Time Frame: After 90 days of treatment ] [ Designated as safety issue: No ]
  • Additional resources in the event of attacks [ Time Frame: After 90 days of treatment ] [ Designated as safety issue: No ]
  • Improvement in the quality of life. [ Time Frame: After 90 days of treatment ] [ Designated as safety issue: No ]
  • Increase in the weekly number of nocturnal awakening or the number of awakenings per night [ Time Frame: After 90 days of treatment ] [ Designated as safety issue: No ]
  • Increase in the use of rescue drug [ Time Frame: After 90 days of treatment ] [ Designated as safety issue: No ]

Enrollment: 472
Study Start Date: May 2004
Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
telephone follow-up
Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
Other: Telephone follow-up
Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
No telephone follow-up
Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
Other: No telephone follow-up
Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.

  Hide Detailed Description

Detailed Description:

Objectives

General:

To evaluate the compliance degree to the treatment of asthmatic children, according to the attention received.

Specific:

  1. To study asthmatic compliance to the treatment proposed, aiming at an association with other factors, such as: parents' instruction, hospitalizations, personal and family history of atopy, co-morbidities, severity of the disease and use of other drugs.
  2. To study asthmatic compliance to the treatment proposed, associating it with the impact in quality of life, though the application of a specific questionnaire.

Outcomes

The main outcome, compliance, is being measured by the number of doses used of the drug salmeterol combined with fluticasone (Seretide Diskus) divided by the number of doses foreseen for the time considered.

The following will be considered as secondary outcomes:

  • Disease control, evaluated by information in the questionnaires.
  • Regular medical attention sought, evaluated by information in the questionnaires.
  • Additional resources in the event of attacks, increase in the weekly number of nocturnal awakening or the number of awakenings per night, increase in the use of rescue drug.
  • Improvement in the quality of life.

Casuistic and Method

Study groups

Asthmatic children aged 6 to 14 years old from both sexes, with persistent mild, moderate or sever asthma classified according to the criteria from the III - Brazilian Consensus on Asthma Management.

Group I - Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.

Group II - Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.

Study Design

This is a prospective, controlled, randomized, parallel-group study, with the inclusion of 472 children presenting persistent moderate or severe asthma. Our researchers developed the study, and it will be performed only in Brazil, solely by our Clinical Research Center. The drug to be used is in accordance with the main International Consensus on Asthma Treatment and with the III - Brazilian Consensus on Asthma Management, being marketed for some years in Brazil.

During patient recruitment and screening, their parents or guardians will fill out the free informed consent form. At this time, they will also be given the drug (Seretide Diskus® 50/250) with doses enough for a 90-day treatment, twice a day, in addition to instructions on the use of the device to apply the drug and guidance from his/her physician on how to act in the event of an attack.

After study inclusion, the study will receive a number which will randomly include him/her in group 1 or 2 of this study.

Patients included in group 1 will receive two types of telephone calls:

A. Investigation telephone call - TI: that will be made by a trained health professional from the Centro de Pesquisa Clínica e Medicina Avançada, aiming at: presentation, data collection on asthma, including demographics and relevant clinical history (details on asthma, previous exacerbations, drugs used, etc), submission of a standardized checking questionnaire (questionnaire 1 - attachment 1) and quality of life questionnaire (questionnaire 2 - attachment 2). By 90 days, the patient's guardian will receive the last investigation telephone call (TI -2) in order to apply the quality of life questionnaire and standardized evaluation questionnaire (questionnaire 1 - attachment 1)

B. Compliance telephone call - TA: A specifically trained professional will make follow-up telephone calls at every fifteen days, according to a pre-established guide (Attachment 4), requesting the patient to answer the questions pursuant to the follow-up questionnaire (attachment 3) and clarifying probable doubts on the drug application, however, without interfering with the treatment prescribed by the physician.

Patients included in group 2 will receive only the Investigation Telephone call (TI) All telephone contacts will be made for the same person: mother, father or guardian.

By the end of week 12, the persons responsible for the patients will return, by mail, the drug to Centro de Pesquisa Clínica e Medicina Avançada.

  Eligibility

Ages Eligible for Study:   6 Years to 14 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Signature of a informed consent form
  • Age between 6 and 14 years old
  • Diagnosis of persistent moderate or severe asthma, according to III Brazilian Consensus on Asthma Management.
  • Home telephone available

Exclusion criteria:

  • Co-morbidities that may interfere with the study evaluation or that require continuous drugs, e.g., cardiopathy, gastro-esophageal reflux or diabetes.
  • Continuous systemic corticosteroid use for more than seven days
  • The patient has been treated or is being treated with allergen-specific immunetherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01476059

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT01476059     History of Changes
Other Study ID Numbers: 113244
Study First Received: March 4, 2010
Last Updated: November 17, 2011
Health Authority: Brazil: Institutional Review Board

Keywords provided by GlaxoSmithKline:
Treatment compliance
Pediatric
Asthma

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Salmeterol
Fluticasone
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Dermatologic Agents
Anti-Allergic Agents
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on July 24, 2014